AI English summary of an SEC filing — figures as filed
Cardinal Health CAHCardinal Health entered into a Term Loan Credit Agreement with Bank of America, N.A. as Administrative Agent on December 5, 2024. The agreement provides commitments for a term loan facility totaling $1.0 billion. Once borrowed, loans will mature 3 years after the borrowing date.
Key points
AI summaryCardinal Health entered into a Term Loan Credit Agreement with Bank of America, N.A. as Administrative Agent on December 5, 2024. The agreement provides commitments for a term loan facility totaling $1.0 billion. Once borrowed, loans will mature 3 years after the borrowing date.
The company said the term loan commitments remain available until the earliest of the following: both termination dates under the merger agreements have occurred, both transactions under the merger agreements close without the loans being funded, or November 10, 2025. Borrowing rates will be based on Term SOFR and will depend on the company's credit ratings.
The company said it may use loans under the credit agreement to pay the cash consideration for either or both of its acquisitions of a majority stake in The GI Alliance Holdings, LLC and Advanced Diabetes Supply Group, along with transaction costs and expenses. The merger agreements are dated November 11, 2024.
The company said the financial covenant requires it to maintain a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The agreement also includes customary covenants, including restrictions on liens, subsidiary debt and contingent obligations, as well as customary events of default.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
$1.0 billion Term Loan Credit Agreement Signed
Cardinal Health entered into a Term Loan Credit Agreement with Bank of America, N.A. as Administrative Agent on December 5, 2024. The agreement provides commitments for a term loan facility totaling $1.0 billion. Once borrowed, loans will mature 3 years after the borrowing date.
Source · Based on the filing body and exhibits
Credit Agreement Term and Interest Rate Basis
The company said the term loan commitments remain available until the earliest of the following: both termination dates under the merger agreements have occurred, both transactions under the merger agreements close without the loans being funded, or November 10, 2025. Borrowing rates will be based on Term SOFR and will depend on the company's credit ratings.
Source · Based on the filing body and exhibits
Use of Proceeds: Cash Consideration and Transaction Costs for Mergers
The company said it may use loans under the credit agreement to pay the cash consideration for either or both of its acquisitions of a majority stake in The GI Alliance Holdings, LLC and Advanced Diabetes Supply Group, along with transaction costs and expenses. The merger agreements are dated November 11, 2024.
Source · Based on the filing body and exhibits
Financial Covenant: Consolidated Net Leverage Ratio of 3.75 to 1.00 or Less
The company said the financial covenant requires it to maintain a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The agreement also includes customary covenants, including restrictions on liens, subsidiary debt and contingent obligations, as well as customary events of default.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…